Alzheimer disease therapy: Can the amyloid cascade be halted?

Journal of Clinical Investigation

Volumn 111, Issue 1, 2003, Pages 11-18

  Golde, Todd E ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CLIOQUINOL; ENZYME INHIBITOR; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IBUPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; STATIN; SULINDAC; UNCLASSIFIED DRUG; WORTMANNIN;

AGING; ALZHEIMER DISEASE; ANIMAL MODEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CRYSTAL STRUCTURE; DISEASE COURSE; DRUG TOLERABILITY; EPIDEMIOLOGICAL DATA; FOOD AND DRUG ADMINISTRATION; GENETIC PREDISPOSITION; HUMAN; IMMUNIZATION; INHIBITION KINETICS; MOUSE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN METABOLISM; REGULATORY MECHANISM; REVIEW; RISK ASSESSMENT; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; CHOLESTEROL; HUMANS; MODELS, BIOLOGICAL; RISK FACTORS;

EID: 0037248301     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317527     Document Type: Review

References (102)

1. Small, G.W., et al. 1997. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 278:1363-1371.
2. Rice, D.P., et al. 2001. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Am. J. Manag. Care. 7:809-818.
3. Fillit, H., Hill, J.W., and Fufferman, R. 2002. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy. Fam. Med. 34:528-535.
4. Crook, R., et al. 1998. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion ofexon 9 of presenilin 1. Nat. Med. 4:452-455.
5. Kwok, J.B., et al. 1997. Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype. Neuroreport. 8:1537-1542.
6. Golde, T.E., Eckman, C.B., and Younkin, S.G. 2000. Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim. Biophys. Acta. 1502:172-187.
7. Golde, T.E., and Younkin, S.G. 2001. Presenilins as therapeutic targets for the treatment of Alzheimer's disease. Trends Mol. Med. 7:264-269.
8. Hardy, J. 1997. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20:154-159.
9. Younkin, S.G. 1998. The role of A beta 42 in Alzheimer's disease. J. Physiol. Paris. 92:289-292.
10. Selkoe, DJ. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:741-766.
11. Nilsberth, C., et al. 2001. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci. 4:887-893.
12. Scheuner, D., et al. 1996. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's discase. Nat. Med. 2:864-870.
13. Holtzman, D.M., et al. 2000. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 47:739-747.
14. Jarrett, J.T., Berger, E.P., and Lansbury, P.T., Jr. 1993. The carboxy terminus of β amyloid protein is critical for the seeding of amyloid formation: implications for pathogenesis of Alzheimer's disease. Biochemistry. 32:4693-4697.
15. Price, D.L., and Sisodia, S.S. 1998. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21:479-505.
16. Yankner, B.A. 1996. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 16:921-932.
17. Vidal, R., et al. 1999. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature. 399:776-781.
18. Vidal, R., et al. 2000. A decamer duplication in the 3′ region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc. Natl. Acad. Sci. USA. 97:4920-4925.
19. Hardy, J.A., and Higgins, G.A. 1992. Alzheimer's disease: the amyloid cascade hypothesis. Science. 256:184-185.
20. Lambert, M.P., et al. 1998. Diffusible, nonfibrillar ligands derived from Abeta 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA. 95:6448-6453.
21. Walsh, D.M., Lomakin, A., Benedek, G.B., Condron, M.M., and Teplow, D.B. 1997. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272:22364-22372.
22. Lashuel, H.A., Hartley, D., Petre, B.M., Walz, T., and Lansbury, P.T., Jr. 2002. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 418:291.
23. LaFerla, F.M., Tinkle, B.T., Bieberich, C.J., Haudenschild, C.C., and Jay, G. 1995. The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat. Genet. 9:21-30.
24. Gouras, G.K., et al. 2000. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 156:15-20.
25. Price, D.L., Tanzi, R.E., Borchelt, D.R., and Sisodia, S.S. 1998. Alzheimer's disease: generic studies and transgenic models. Annu. Rev. Genet. 32:461-493.
26. Small, D.H., Mok, S.S., and Bornstein, J.C. 2001. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat. Rev. Neurosci. 2:595-598.
27. Akiyama, H., et al. 2000. Inflammation and Alzheimer's disease. Neurobiol. Aging. 21:383-421.
28. Varadarajan, S., Yatin, S., Aksenova, M., and Butterfield, D.A. 2000. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130:184-208.
29. Lee, V.M.-Y., and Trojanowski, J.Q. 1992. The disordered neuronal cytoskeleton in Alzheimer's disease. Curr. Opin. Neurobiol. 2:653-656.
30. Hutton, M., et al. 1998. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 393:702-705.
31. Spillantini, M.G., et al. 1998. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA. 95:7737-7741.
32. Lewis, J., et al. 2000. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25:402-405.
33. Gotz, J., Chen, F., van Dorpe, J., and Nitsch, R.M. 2001. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science. 293:1491-1495.
34. Lewis, J., et al. 2001. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 293:1487-1491.
35. Evin, G., et al. 2001. Aspartyl protease inhibitor pepstatin binds to the presenilins of Alzheimer's disease. Biochemistry. 40:8359-8368.
36. Li, Y.M., et al. 2000. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 405:689-694.
37. Esler, W.P., et al. 2000. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat. Cell Biol. 2:428-434.
38. Seiffert, D., et al. 2000. Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J. Biol. Chem. 275:34086-34091.
39. Dovey, H., Varghese, J., and Anderson, J.P. 2000. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in the brain. J. Neurochem. 76:1-10.
40. De Strooper, B., et al. 1999. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 398:518-522.
41. Hadland, B.K., et al. 2001. Gamma-secretase inhibitors repress thymocyte development. Proc. Natl. Acad. Sci. USA. 98:7487-7491.
42. Ni, C.Y., Murphy, M.P., Golde, T.E., and Carpenter, G. 2001. γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science. 294:2179-2181.
43. Kammesheidt, A., et al. 1992. Deposition of β/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor in the brain. Proc. Natl. Acad. Sci. USA. 89:10857-10861.
44. Yankner, B.A., et al. 1989. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 245:417-420.
45. Cai, H., et al. 2001. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 4:233-234.
46. Luo, Y., et al. 2001. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 4:231-232.
47. Hong, L., et al. 2002. Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3. Biochemistry. 41:10963-10967.
48. Hong, L., et al. 2000. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science. 290:150-153.
49. Weggen, S., et al. 2001. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 414:212-216.
50. Lim, G.P., et al. 2000. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20:5709-5714.
51. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G.G., and Siegel, G. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57:1439-1443.
52. Jick, H., Zornberg, G.L., Jick, S.S., Seshadri, S., and Drachman, D.A. 2000. Statins and the risk of dementia. Lancet. 356:1627-1631.
53. Jarvik, G.P., et al. 1995. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology. 45:1092-1096.
54. Notkola, I.L., et al. 1998. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 17:14-20.
55. Hofman, A., et al. 1997. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 349:151-154.
56. Kivipelto, M., et al. 2001. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 322:1447-1451.
57. Simons, M., et al. 1998. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA. 95:6460-6464.
58. Refolo, L.M., et al. 2001. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8:890-899.
59. Fassbender, K., et al. 2001. Simvastarin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 98:5856-5861.
60. Refolo, L.M., et al. 2000. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7:321-331.
61. Puglielli, L., et al. 2001. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3:905-912.
62. Golde, T.E., and Eckman, C.B. 2001. Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. Drug Discov. Today. 6:1049-1055.
63. Wolozin, B. 2001. A fluid connection: cholesterol and Abeta. Proc. Natl. Acad. Sci. USA. 98:5371-5373.
64. Snowdon, D.A., et al. 1997. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 277:813-817.
65. Haugabook, S.J., et al. 2001. Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin. FASEB J. 15:16-18.
66. Soto, C. 1999. Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol. Med. Today. 5:343-350.
67. Permanne, B., et al. 2002. Reduction ofamyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J. 16:860-862.
68. Sigurdsson, E.M., Permanne, B., Soto, C., Wisniewski, T., and Frangione, B. 2000. In vivo reversal of amyloid-beta lesions in rat brain. J. Neuropathol. Exp. Neurol. 59:11-17.
69. Cherny, R.A., et al. 2001. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 30:665-676.
70. Curtain, C.C., et al. 2001. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem. 276:20466-20473.
71. Schenk, D., et al. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:173-177.
72. Lemere, C.A., et al. 2000. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. NY Acad. Sci. 920:328-331.
73. DeMattos, R.B., et al. 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 98:8850-8855.
74. Janus, C., et al. 2000. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:979-982.
75. Bard, F., et al. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:916-919.
76. Das, P., Murphy, M.P., Younkin, L.H., Younkin, S.G., and Golde, T.E. 2001. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging. 22:721-727.
77. Morgan, D., et al. 2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:982-985.
78. Bacskai, B.J., et al. 2001. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7:369-372.
79. Das, P., and Golde, T.E. 2002. Open peer commentary regarding Abeta immunization and CNS inflammation by Pasinetti et al. Neurobiol. Aging. 23:671-674.
80. Hock, C., et al. 2002. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 8:1270-1275.
81. Schenk, D. 2002. Opinion. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3:824-828.
82. Lemere, C.A., et al. 1996. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3:16-32.
83. Chan, D., et al. 2001. Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology. 57:1756-1763.
84. Fox, N.C., et al. 2001. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet. 358:201-205.
85. Breitner, J.C., et al. 1994. Alzheimer's disease in the NAS-NRC registry of aging twin veterans. II. Longitudinal findings in a pilot series. National Academy of Sciences. National Research Council Registry. Dementia. 5:99-105.
86. Rubinsztein, D.C. 1997. The genetics of Alzheimer's disease. Prog. Neurobiol. 52:447-454.
87. Roses, A.D. 1997. Apolipoprotein E, a gene with complex biological interactions in the aging brain. Neurobiol. Dis. 4:170-185.
88. Kehoe, P., et al. 1999. A full genome scan for late onset Alzheimer's disease. Hum. Mol. Genet. 8:237-245.
89. Myers, A., et al. 2000. Susceptibility locus for Alzheimer's disease on chromosome 10. Science. 290:2304-2305.
90. Errekin-Taner, N., et al. 2000. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science. 290:2303-2304.
91. Bertram, L., et al. 2000. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science. 290:2302-2303.
92. Galasko, D. 2001. Biological markers and the treatment of Alzheimer's disease. J. Mol. Neurosci. 17:119-125.
93. Boss, M.A. 2000. Diagnostic approaches to Alzheimer's disease. Biochim. Biophys. Acta. 1502:188-200.
94. Pratico, D., et al. 2000. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 48:809-812.
95. Montine, T.J., et al. 2001. Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch. Pathol. Lab. Med. 125:510-512.
96. Ertekin-Taner, N., et al. 2001. Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees. Genet. Epidemiol. 21:19-30.
97. Mayeux, R., et al. 1999. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann. Neurol. 46:412-416.
98. Schupf, N., et al. 2001. Elevated plasma amyloid beta-pepride 1-42 and onset of dementia in adults with Down syndrome. Neurosci. Lett. 301:199-203.
99. Skovronsky, D.M., et al. 2000. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 97:7609-7614.
100. Klunk, W.E., et al. 2002. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J. Neuropathol. Exp. Neurol. 61:797-805.
101. Jack, C.R., Jr., et al. 2002. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 58:750-757.
102. Bacskai, B.J., Klunk, W.E., Mathis, C.A., and Hyman, B.T. 2002. Imaging amyloid-beta deposits in vivo. J. Cereb. Blood Flow Metab. 22: 1035-1041.